So many folks accuse Asensio of pulling his "losing" releases off of his website, that I thought it might be a good idea if we post them here, "for the record". I don't think that any are missing since I started following him a little over a year ago, but I'm getting tired of trying to prove that he hasn't removed something. Also, I guess I could have forgotten one or two. I also think only the initial sell rec is the really important one. So anyway, here's today's release below.
Barb
----------------------------------------------------------------------
Asensio & Company: AMA Denies Permitting Insurance Reimbursement for
CCSI
NEW YORK, June 23 /PRNewswire/ -- Asensio & Company, Inc. released the following statement today:
In a press release dated March 16, 1998 Chromatics Color Sciences International, Inc. (OTC Bulletin Board: CCSI - news)
announced it ''has received a letter from the American Medical Association permitting 3rd party insurance reimbursement in all
U.S. states for each use of the Company's non-invasive device under AMA Code CPT 82250, which is the same reimbursement
code for the laboratory blood test currently used to monitor hyperbilirubinemia.'' The American Medical Association (''AMA'') has
confirmed that it has not sent any such letter to Chromatics, that the AMA CPT code 82250 should not be used for Chromatics'
Colormate III jaundice product, that the AMA does not have a CPT code for a non-invasive test to estimate bilirubin blood levels,
and that AMA CPT codes do not under any condition obligate or permit any insurance company to reimburse hospitals or patients
for any charges. A copy of our complete report on the AMA's position is available on the Internet at asensio.com.
Chromatics has admitted that it ''never considered'' instrument sales to have ''major income potential'' in the bilirubin market. It
claims that a majority of its revenues will come from sales of a disposable calibration and contamination guard that will be required
for each test performed using its instrument. This means that the Chromatics device needs to be recalibrated, or at least verified,
after each use and that it requires contact with the patient's skin. These characteristics are crude and totally unnecessary. Simple
inexpensive color measurement devices are readily available that can perform the required operation precisely without physical
contact or the need for recalibration after each use.
Most babies are not subjected to blood tests for jaundice. In fact, in Chromatics' clinical trials submitted to the FDA 1,037 of the
1,317 babies in the trial did not undergo blood tests. The jaundice test is simple and relatively painless. The bilirubin test does not
require blood to be drawn from a vein. It uses a drop of blood obtained from the capillaries of the heel. The Chromatics test can
only be used to estimate total bilirubin levels. It cannot replace a blood test. Chromatics has refused to state the sale price of its
disposable. The current blood test costs hospitals less than $1 per test. There is no reason to believe any hospital will pay
Chromatics or any other colorimeter provider a significant per test charge for an unnecessary test that requires an unnecessary
disposable.
Asensio & Company is a New York based institutional investment bank specializing in corporate valuations and equity research.
Asensio & Company also specializes in investigating fraudulent stock promotions and publishing research on grossly overvalued
companies. Asensio & Company's complete report on Chromatics' disposable charges and insurance reimbursement claims is
available on its Internet home page located at asensio.com.
SOURCE: Asensio & Company, Inc. |
